Phase 3 Myasthenia Gravis Trial, Recruiting (NCT06456580)

Phase 3 Myasthenia Gravis Trial, Recruiting NCT06456580 Sponsor: Vor Biopharma Condition: Myasthenia Gravis

Printed from Voxsanity (voxsanity.com.au) — NCT06456580 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myasthenia Gravis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years old or older
You have already been diagnosed with generalized Myasthenia Gravis (MG), a condition that causes widespread muscle weakness affecting more than just the eyes
A blood test has confirmed you have specific antibodies (AChR or MuSK) linked to MG, tested at the start of the study
Your MG symptoms score at least 6 points on a daily activities scale, and your eye-related symptoms make up less than half of that total score (confirm with trial site)
Your muscle weakness scores high enough on a specific strength test used for MG (confirm with trial site for exact scoring details)

Who may not be able to join:

You have been diagnosed with another autoimmune disease (a condition where the immune system attacks the body)
You currently have or are being treated for an infection, either short-term or long-term
You have had a thymus gland tumour (thymoma) in the last 5 years, or had your thymus removed within the last 6 months (some exceptions may apply — confirm with trial site)
You have a current or past diagnosis of a condition where your immune system does not work properly from birth or early life
You have had any type of cancer in the last 5 years
You have a serious ongoing condition affecting your heart, liver, kidneys, lungs, hormones, or blood

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 617-655-6580

Australian sites

Concord Repatriation General Hospital, Concord, New South Wales

Townsville University Hospital, Douglas, Queensland

Gold Coast University Hospital, Southport, Queensland

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06456580

Sponsor: Vor Biopharma

Phase: Phase 3

Status: Recruiting

Condition: Myasthenia Gravis

Trial contact: 617-655-6580

More information: https://clinicaltrials.gov/study/NCT06456580

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years old or older
You have already been diagnosed with generalized Myasthenia Gravis (MG), a condition that causes widespread muscle weakness affecting more than just the eyes
A blood test has confirmed you have specific antibodies (AChR or MuSK) linked to MG, tested at the start of the study
Your MG symptoms score at least 6 points on a daily activities scale, and your eye-related symptoms make up less than half of that total score (confirm with trial site)
Your muscle weakness scores high enough on a specific strength test used for MG (confirm with trial site for exact scoring details)

Who may not be able to join:

You have been diagnosed with another autoimmune disease (a condition where the immune system attacks the body)
You currently have or are being treated for an infection, either short-term or long-term
You have had a thymus gland tumour (thymoma) in the last 5 years, or had your thymus removed within the last 6 months (some exceptions may apply — confirm with trial site)
You have a current or past diagnosis of a condition where your immune system does not work properly from birth or early life
You have had any type of cancer in the last 5 years
You have a serious ongoing condition affecting your heart, liver, kidneys, lungs, hormones, or blood

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Vor Biopharma

Registry

ClinicalTrials.gov

Start date

17 July 2024

Est. completion

1 May 2027

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇨🇿 Czechia 🇫🇷 France 🇬🇪 Georgia 🇮🇹 Italy 🇯🇵 Japan 🇵🇱 Poland 🇪🇸 Spain 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov